The strong efficacy and durability data position CUE-221 as a potential best-in-class therapy for CSU, with a clear path to Phase 2b/3. The upcoming conference call on September 21 may provide additional details on trial design and regulatory strategy. Monitor for initiation of the Phase 2b/3 study and any partnership or financing announcements to fund development.
Price Chart
Executive Summary
Cue Biopharma announced positive Phase 2 topline results for CUE-221 in chronic spontaneous urticaria (CSU), meeting the primary endpoint (HSS7=0) with high statistical significance at all dose levels and the key secondary endpoint (UAS7=0) at the 4 mg/kg dose. The data suggest superior efficacy versus XOLAIR (omalizumab), with a favorable safety profile and durable response up to 12 weeks off treatment. The company plans to initiate a Phase 2b/3 study in CSU and a Phase 2 study in food allergy.
Key Facts
- Primary endpoint (HSS7=0 at week 12) met with statistical significance at all three CUE-221 dose levels: 54% (4 mg/kg, p<0.005), 53% (2 mg/kg, p<0.005), 43% (1 mg/kg, p<0.05) vs 11% placebo.
- Key secondary endpoint (UAS7=0 at week 12) met at 4 mg/kg (46%, p<0.05) vs 11% placebo and 29% omalizumab.
- Peak effect at week 22: 69% (4 mg/kg) achieved HSS7=0, vs 41% omalizumab and 11% placebo.
- At week 28 (12 weeks off drug), 60% of 4 mg/kg group maintained HSS7=0 vs 24% omalizumab (delta=36%, p<0.05).
- No treatment-related serious adverse events, no anaphylaxis, and only one injection site reaction > grade 1; none led to discontinuation.
- Company plans to initiate Phase 2b/3 study in CSU and Phase 2 study in food allergy.
Financial Impact
Positive Phase 2 data for lead asset CUE-221 in a large market (CSU) with potential superiority over standard-of-care XOLAIR; no financial figures disclosed.
Risk Factors
- Data are from a Phase 2 trial conducted in China; results may not replicate in larger, global Phase 2b/3 studies.
- Company is clinical-stage with no approved products; will require additional capital to fund late-stage development.
- Competition from XOLAIR and other emerging anti-IgE therapies could limit commercial uptake.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3365072 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | Insider Cluster | $18.67 $16.71 | ▲ +10.50% | ▲ +9.39% | $18.45 (+1.18%) |
Oct 13, 2026 12d ago | 144 | $18.60 $18.67 | ▲ +0.38% | ▲ +0.09% | $18.45 (−0.81%) |
Oct 8, 2026 18d ago | SC 13G/A | $22.33 $27.66 | ▲ +23.87% | ▲ +23.27% | $18.45 (−17.38%) |
Sep 21, 2026 5w ago | 8-K | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.45 (−34.74%) |
Sep 20, 2026 5w ago | Press Release | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.45 (−34.74%) |
Aug 21, 2026 9w ago | EFFECT | $23.98 $23.18 | ▲ +3.34% | ▲ +3.04% | $18.45 (+23.06%) |
Aug 17, 2026 9w ago | Insider Cluster | $25.70 $26.28 | ▼ −2.26% | ▼ −2.05% | $18.45 (+28.21%) |
Aug 14, 2026 10w ago | Press Release | $27.64 $25.70 | ▼ −7.02% | ▼ −6.34% | $18.45 (−33.25%) |
Aug 13, 2026 10w ago | 144 | $34.20 $27.64 | ▼ −19.18% | ▼ −18.71% | $18.45 (−46.05%) |
Jul 9, 2026 15w ago | Press Release | $36.78 $30.92 | ▼ −15.93% | ▼ −15.17% | $18.45 (−49.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers